Journal article
Picking the optimal target for antibody-drug conjugates
American Society of Clinical Oncology educational book, Vol.33, pp.e103-e107
2013
DOI: 10.1200/EdBook_AM.2013.33.e103
PMID: 23714470
Abstract
Antibody-drug conjugates (ADCs) combine the cytotoxic potential of chemotherapeutic drugs with the specificity of monoclonal antibodies (mAbs). After many years of unfulfilled promise, the field of ADCs is experiencing resurgence as more is learned about each of the components of an ADC and how these components need to be combined to produce a successful therapeutic agent. Choosing an appropriate target for ADCs is a critical parameter that effects the efficacy, therapeutic window, and toxicity profile of ADCs. This review will focus on the concepts underlying the choice of the target, review specific current ADCs and their targets, and look to the future of ADCs.
Details
- Title: Subtitle
- Picking the optimal target for antibody-drug conjugates
- Creators
- Rohan Mathur - HoldenGeorge J Weiner - Holden
- Resource Type
- Journal article
- Publication Details
- American Society of Clinical Oncology educational book, Vol.33, pp.e103-e107
- DOI
- 10.1200/EdBook_AM.2013.33.e103
- PMID
- 23714470
- ISSN
- 1548-8756
- eISSN
- 1548-8756
- Language
- English
- Date published
- 2013
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359938802771
Metrics
18 Record Views